AstraZeneca (LON:AZN) Price Target Cut to GBX 9,900 by Analysts at UBS Group

AstraZeneca (LON:AZNFree Report) had its price objective lowered by UBS Group from £107 ($135.14) to GBX 9,900 ($125.03) in a research note released on Monday, reports. The brokerage currently has a sell rating on the biopharmaceutical company’s stock.

AZN has been the subject of a number of other reports. Shore Capital reaffirmed a buy rating on shares of AstraZeneca in a research report on Thursday, February 8th. Citigroup reaffirmed a buy rating on shares of AstraZeneca in a report on Tuesday, November 28th. JPMorgan Chase & Co. reiterated an overweight rating on shares of AstraZeneca in a report on Friday, November 17th. Jefferies Financial Group reduced their price objective on AstraZeneca from £130 ($164.18) to £125 ($157.87) and set a buy rating for the company in a research note on Monday, November 27th. Finally, Barclays reiterated a buy rating and set a £135 ($170.50) target price on shares of AstraZeneca in a research note on Monday, November 20th. One analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the company’s stock. Based on data from, the company presently has an average rating of Moderate Buy and a consensus target price of £122.75 ($155.03).

Get Our Latest Report on AZN

AstraZeneca Stock Performance

LON AZN opened at GBX 9,637.63 ($121.72) on Monday. The company has a fifty day moving average price of £104.56 and a 200-day moving average price of £105.81. The firm has a market cap of £149.38 billion, a price-to-earnings ratio of 3,146.03, a PEG ratio of 0.47 and a beta of 0.19. The company has a debt-to-equity ratio of 75.70, a current ratio of 0.82 and a quick ratio of 0.59. AstraZeneca has a 1 year low of GBX 9,461 ($119.49) and a 1 year high of £123.92 ($156.50).

AstraZeneca Increases Dividend

The company also recently disclosed a dividend, which will be paid on Monday, March 25th. Investors of record on Thursday, February 22nd will be paid a GBX 156 ($1.97) dividend. This is a boost from AstraZeneca’s previous dividend of $71.80. This represents a yield of 1.49%. The ex-dividend date is Thursday, February 22nd. AstraZeneca’s payout ratio is currently 7,549.67%.

Insiders Place Their Bets

In other AstraZeneca news, insider Michel Demare purchased 1,000 shares of the stock in a transaction dated Wednesday, November 22nd. The shares were bought at an average price of £101.70 ($128.44) per share, with a total value of £101,700 ($128,441.53). In related news, insider Anna Manz acquired 487 shares of the company’s stock in a transaction that occurred on Tuesday, December 12th. The shares were acquired at an average price of £101.90 ($128.69) per share, with a total value of £49,625.30 ($62,674.03). Also, insider Michel Demare bought 1,000 shares of the business’s stock in a transaction on Wednesday, November 22nd. The stock was bought at an average price of £101.70 ($128.44) per share, with a total value of £101,700 ($128,441.53). Company insiders own 0.21% of the company’s stock.

About AstraZeneca

(Get Free Report)

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, andcommercialization of prescription medicines. The company's marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Andexxa/Ondexxya, Atacand, Atacand HCT, Atacand Plus, Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, Xigduo/Xigduo, and Zestril XR for cardiovascular, renal, and metabolism diseases; Accolate, Accoleit, Vanticon, Bevespi Aerosphere, Breztri Aerosphere, Bricanyl Respules and Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Rhinocort, Saphnelo, Symbicort, and Tezspire for respiratory and immunology; and Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.

See Also

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with's FREE daily email newsletter.